2,4-Diarylthiazole antiprion compounds as a novel structural class of antimalarial leads

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 12, 2011, Pages 3644-3647

  Thompson, Mark J ^a   Louth, Jennifer C ^a   Little, Susan M ^b   Chen, Beining ^a   Coldham, Iain ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Amines; Dual activity; Malaria; Prion diseases; Thiazoles

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANTIMALARIAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRION DISEASE; STRUCTURE ACTIVITY RELATION;

ANTIMALARIALS; CHLOROQUINE; MEFLOQUINE; MOLECULAR STRUCTURE; PLASMODIUM FALCIPARUM; PRIONS; QUINACRINE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

PLASMODIUM FALCIPARUM;

EID: 79957872486     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.04.090     Document Type: Article

References (21)

1. World Health Organization, World Malaria Report 2010; http://www.who.int/malaria/world-malaria-report-2010/en/index.html (accessed 02/12/11).
2. Doh-Ura, K.; Iwaki, T.; Caughey, B. J. Virol. 2000, 74, 4894.
3. Korth, C.; May, B. C. H.; Cohen, F. E.; Prusiner, S. B. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 9836.
4. Barret, A.; Tagliavini, F.; Forloni, G.; Bate, C.; Salmona, M.; Colombo, L.; DeLuigi, A.; Limido, L.; Suardi, S.; Rossi, G.; Auvré, F.; Adjou, K. T.; Salès, N.; Williams, A.; Lasmézas, C.; Deslys, J. P. J. Virol. 2003, 77, 8462.
5. Furukawa, H.; Mitsuo, T.; Masashi, N.; Tatsuo, Y. Nippon Rinsho 2002, 60, 1649.
6. Nakajima, M.; Yamada, T.; Kusuhara, T.; Furukawa, H.; Takahashi, M.; Yamauchi, A.; Kataoka, Y. Dement. Geriatr. Cogn. 2004, 17, 158.
7. Hak, S.; Brandel, J. P.; Salomon, D.; Sazdovitch, V.; Delasnerie-Lauptre, N.; Laplanche, J. L.; Faucheux, B. A.; Soubrié, C.; Boher, E.; Belorgey, C.; Hauw, J. J.; Alpérovitch, A. Neurology 2004, 63, 2413.
8. Collinge, J.; Gorham, M.; Hudson, F.; Kennedy, A.; Keogh, G.; Pal, S.; Rossor, M.; Rudge, P.; Siddique, D.; Spyer, M.; Thomas, D.; Walker, S.; Webb, T.; Wroe, S.; Darbyshire, J. Lancet Neurol. 2009, 8, 334.
9. Klingenstein, R.; Melnyk, P.; Leliveld, S. R.; Ryckebusch, A.; Korth, C. J. Med. Chem. 2006, 49, 5300.
10. Thompson, M. J.; Louth, J. C.; Greenwood, G. K.; Sorrell, F. J.; Knight, S. G.; Adams, N. B. P.; Chen, B. Chem. Med. Chem. 2010, 5, 1476.
11. 50 values computed using GRAPHPAD Prism 4.0 (GraphPad Software Inc.).
12. Desjardins, R. J.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Antimicrob. Agents Chemother. 1979, 16, 710.
13. Thompson, M. J.; Louth, J. C.; Ferrara, S.; Sorrell, F. J.; Irving, B. J.; Cochrane, E. J.; Meijer, A. J. H. M.; Chen, B. Chem. Med. Chem. 2011, 6, 115.
14. Thompson, M. J.; Borsenberger, V.; Louth, J. C.; Judd, K. E.; Chen, B. J. Med. Chem. 2009, 52, 7503.
15. -1; UV detection at λ 254 nM).
16. 4OS requires 389.1436); HPLC purity 99.9%.
17. 3OS requires 422.2266); HPLC purity 100%.
18. 3OS requires 432.2110); HPLC purity 98.0%.
19. 3OS requires 418.1953); HPLC purity 99.1%.
20. 3OS requires 372.1171); HPLC purity 99.5%.
21. Birkett, C. R.; Hennion, R. M.; Bembridge, D. A.; Clarke, M. C.; Chree, A.; Bruce, M. E.; Bostock, C. J. EMBO J. 2001, 20, 3351.